[ad_1]
Having obtained the green light in the United States, Europe also approves the first "anti-cancer" therapy based on the "Car-t" technique, which involves the use of "trained" patient cells to recognize tumors
The green disk for Kymriah comes from the Chmp, the Ema committee that deals with drug approvals.
Two insidious enemies of the blood
The positive opinion, which will now have to be confirmed by the European Commission, includes two aggressive neoplasms, Acute Lymphoblastic Leukemia (ALL) in B cells in patients up to 19 years old. at 25 years of age and spread B-cell lymphoma (DLBCL) in adults, and in both cases, should be used for forms that do not respond to traditional therapies.
The patient's lymphocytes are taken
The basket therapy consists in removing the T lymphocytes from the patient, a type of cells of the immune system, modifying them because they recognize the tumor cells, then reinfondendoli after making them replicate ..
Perhaps a hope of healing in the impossible case
"This therapy offers a hope of healing to a group of patients for whom there was no cure before – explains Franca Fagioli , president of Italian Association of Hematology and Pediatric Oncology – As for leukemia, it could work in 20% of patients for whom the available drugs have no effect, although it must be remembered that it should be administered only in highly specialized centers. "
The Novartis:" 80% of the cases in Europe "
In Europe, a press release of Novartis, which perfected the A therapy, recalls that Lla represents 80% about cases of leukemia, while Dlbcl is the most common subtype of non-Hodgkin's lymphoma. "In Italy, it is estimated that every year 70 to 80 patients with ALL and about 700 for the other pathology could benefit from the therapy – says Paolo Corradini, president of the Italian Society of Hematology – but Car-t is the first antineoplastic cell therapy in the history of humanity, this approval is the first of a long series, as there are promising experiments for many other indications. "[19659010]
[ad_2]
Source link
